Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064753 · ClinicalTrials.gov registry record · Phase 2
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
A Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 4,110
- Enrollment target
- 20
- Study locations
NCT00064753 is a Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 4,110 participants, above the 2,683-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (53% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT00064753, a Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
Conditions Studied
Interventions
- DRUG High Dose Multivitamin
- DEVICE Low Dose Multivitamin
Study Locations (20)
California
- Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation - Los Angeles
- University of California at Los Angeles - Los Angeles
- University of California at San Francisco - San Francisco
Minnesota
- Hennepin County Medical Center - Minneapolis
- Faireview University Medical Center - Minneapolis
- Mayo Clinic - Rochester
Illinois
- Northwestern University - Chicago
- Southern Illinois University - Springfield
New York
- Albany Medical Center - Albany
- State University of New York Downstate Medical Center - Brooklyn
Alabama
- University of Alabama at Birmingham School of Medicine - Birmingham
Arizona
- Banner Good Samaritan Transplant - Phoenix
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,110 participants |
| Start Date | 2002-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064753
The ClinicalTrials.gov registry entry for NCT00064753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4,110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,683-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (53% higher). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which High Dose Multivitamin is the first listed.
NCT00064753 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Minnesota, Illinois.
Frequently Asked Questions
What is clinical trial NCT00064753 about?
NCT00064753 is a clinical study titled "Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)". The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
What is the current status of trial NCT00064753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,110 participants. The study started on 2002-05. Estimated completion is 2011-10.
What conditions does trial NCT00064753 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Chronic Kidney Disease, Death.
What interventions are being tested in trial NCT00064753?
The interventions under investigation include: High Dose Multivitamin (DRUG), Low Dose Multivitamin (DEVICE).
Who is sponsoring clinical trial NCT00064753?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064753 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Reduction of Smoking in Cardiac Disease Patients
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.